Truist Securities Maintains Buy on Globus Medical, Lowers Price Target to $71
Truist Securities analyst Richard Newitter maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $76 to $71.
Truist Securities Maintains Buy on Edwards Lifesciences, Lowers Price Target to $120
Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Buy and lowers the price target from $140 to $120.
Stifel Upgrades Franco-Nevada to Buy, Raises Price Target to C$206
Stifel analyst Ingrid Rico upgrades Franco-Nevada (TSX:FNV) from Hold to Buy and raises the price target from C$205 to C$206.
B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $56
B. Riley Securities analyst Marc Wiesenberger maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $71 to $56.
B. Riley Securities Maintains Buy on Matthews International, Lowers Price Target to $45
B. Riley Securities analyst Liam Burke maintains Matthews International (NASDAQ:MATW) with a Buy and lowers the price target from $50 to $45.
Stifel Maintains Hold on A.O. Smith, Lowers Price Target to $58
Stifel analyst Nathan Jones maintains A.O. Smith (NYSE:AOS) with a Hold and lowers the price target from $59 to $58.
Truist Securities Maintains Buy on Inspired Entertainment, Lowers Price Target to $16
Truist Securities analyst Barry Jonas maintains Inspired Entertainment (NASDAQ:INSE) with a Buy and lowers the price target from $18 to $16.
Stifel Maintains Hold on Badger Meter, Lowers Price Target to $79
Stifel analyst Nathan Jones maintains Badger Meter (NYSE:BMI) with a Hold and lowers the price target from $88 to $79.
Stifel Maintains Hold on Watts Water Technologies, Lowers Price Target to $130
Stifel analyst Nathan Jones maintains Watts Water Technologies (NYSE:WTS) with a Hold and lowers the price target from $141 to $130.
Wells Fargo Maintains Overweight on Omnicom Group, Raises Price Target to $84
Wells Fargo analyst Steven Cahall maintains Omnicom Group (NYSE:OMC) with a Overweight and raises the price target from $73 to $84.